Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

J. Schlom

h-index 13 View on Semantic Scholar

We have 4 of 114 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Long‐Term Oncologic Outcomes of Neoadjuvant Tumor‐Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial

Biochemical recurrence (BCR) following radical prostatectomy (RP) occurs in 20%–40% of patients with localized prostate cancer. Neoadjuvant PROSTVAC has been shown to enhance T‐cell infiltration into the tumor immune microenvironment, but whether these immunologic changes translate into improved long‐term oncologic out...

B. Millan, Alexander P. Kenigsberg, Charles Hesswani et al. · 0 citations
Open access Sep 2026

Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance

Abstract Background Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1+CD8+ T cells, cytotoxic CD8+ T cells, and lymphoid aggregates have been associated with CPB responsiven...

C. Minnar, Masaya Miyamoto, Asma S. Khelifa et al. · 0 citations
Open access Aug 2026

Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator

Administration of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI.

Shantel Angstadt, Lucas A. Horn, Kristen Fousek et al. · 0 citations
Open access Jul 2026

Immunological targeting of the endogenous retroviral protein ERVMER34-1 in carcinomas promotes epitope spread and enhances response to PD-L1 blockade 2306293

The clinical development of a therapeutic cancer vaccine targeting the retroviral envelope protein ERVMER34-1 is supported, which would represent a new class of therapeutic cancer vaccine targeting ERVs.

D. Hamilton, Maria del Mar Maldonado, Renee N. Donahue et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.